New Phase II Data for Nasal Polyposis

December 5, 2007 – OptiNose is pleased to announce the results of a study to investigate the efficacy and tolerability of intranasal fluticasone propionate delivered by the OptiNose liquid nasal drug delivery device in adult patients with bilateral nasal polyposis”. The study in 109 patients was conducted in five centers in the Czech Republic.

The double-blind, randomized, parallel group, placebo-controlled study compared the efficacy, safety and tolerability of fluticasone propionate and placebo when delivered by the OptiNose device in patients with bilateral polyposis.

Patients entering the study received the investigational medicinal product and administered the drug at home in the morning and evening over a three months period.

The results demonstrate that fluticasone propionate at a daily dose of 800 μg administered using the OptiNose device is highly effective in treating mild to moderate nasal polyps and that this method of delivery is safe and very well tolerated. Patient compliance was high.

About OptiNose Inc.

OptiNose is a drug delivery company with breakthrough bi-directional nasal technology set to transform the static nasal drug delivery market. Founded in 2000, OptiNose’s devices are designed to deliver intranasal drugs to target regions of the nasal cavity, including the sinuses and the olfactory region while preventing lung deposition. The company offers both single and multi-use intranasal delivery devices for liquid and powder formulations. The technology has been successfully tested in a number of clinical trials with results confirming the superiority of the technology compared to traditional nasal sprays. Investors in OptiNose include Avista Capital Partners in New York, WFD Ventures LLC located in New York and Entrepreneurs Fund LP based in Jersey, Channel Islands. For more information please visit

About Bi-directional Nasal Delivery Technology

OptiNose’s bidirectional nasal delivery technology significantly improves delivery to the targeted sites deep into the nose. While exhaling into the device, the soft palate automatically closes off the nasal cavity completely. The breath enters one nostril through a sealing nozzle and triggers the release of drug particles into the airflow. This action causes the narrow nasal passages to expand and carry these particles beyond the nasal valve to targeted sites. After delivering drug particles to the targeted sites, the air flow then exits the nasal cavity through the other nasal passage in the opposite direction.

Darren Brandt
(212) 446-1861

Dan Zacchei
(212) 446-1882